Polar X or Arctic Front cryoballoon ablation for persistent atrial fibrillation
- Author:
Hyo Jin LEE
1
;
Su Hyun LEE
;
Juwon KIM
;
Ju Youn KIM
;
Seung-Jung PARK
;
Kyoung-Min PARK
;
Young Keun ON
Author Information
- Publication Type:Research
- From:International Journal of Arrhythmia 2025;26(1):e7-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background and Objectives:Direct head-to-head comparisons between the PolarX and the Arctic Front Advance Pro (AFA-Pro) system remain limited. This study aimed to assess whether the PolarX offers better clinical outcome compared to the AFA-Pro, particularly in patients with persistent AF.
Methods:We performed a retrospective study of 306 patients undergoing cryoballoon ablation from March 2023 to August 2024. This population was divided into two groups based on the duration of AF episode: the paroxysmal AF group (n = 206) and the persistent AF group (n = 100). Among those with persistent AF, there were 47 in the AFA-Pro group and 53 in the PolarX group. The primary outcome was freedom from AF/atrial tachycardia (AT).
Results:In patients with paroxysmal and persistent AF, the mean follow-up durations were 347.1 ± 156.0 days (median, 350.5 days; interquartile range [IQR], 201.8 to 482.5) and 345.5 ± 166.5 days (median, 331.0; IQR, 184.3 to 495.5), respectively. In patients with paroxysmal AF, the PolarX did not improve freedom from AF/AT compared to the AFA-Pro (hazard ratio [HR], 1.23; 95% confidence interval [CI], 0.63 to 2.42; P = 0.546). However, in patients with persistent AF, the PolarX showed a difference in freedom from AF/AT compared to the AFAPro (HR, 0.45; 95% CI, 0.24 to 0.99; P = 0.022).
Conclusions:The use of the PolarX showed a difference in freedom from AF/AT recurrence in patients with persistent AF, which reached statistical significance.
